Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA

This study will evaluate the diagnostic performance of liquid biopsy for identifying molecular abnormalities among patients managed by the Multidisciplinary Molecular Biology Meeting. The gold standard considered in this study is the solid biopsy.

Start Date01 Feb 2025

Sponsor / Collaborator

Centre Antoine-Lacassagne

NCT06627738 / Not yet recruitingPhase 2IIT

Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost

This is a monocentric, non-randomized, open-label, superiority phase II clinical investigation evaluating the efficacy of additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant radiotherapy in patients with locally advanced non-small cell lung carcinoma (NSCLC), with an interim analysis.

Start Date01 Jan 2025

Sponsor / Collaborator

Centre Antoine-Lacassagne

NCT06584747 / Not yet recruitingNot ApplicableIIT

Study of Cerebral Vascular Reserve Using Pharmacological Testing With Acetazolamide: A Non-Inferiority Study of PET Method Compared to Conventional Reference Scintigraphy

This study compares two methods for assessing brain blood flow. PET scan will be use with a drug called Acetazolamide and compare its effectiveness to the standard scintigraphy method. The goal is to see if the PET scan is just as good as the traditional method in measuring how well the brain's blood vessels respond to the drug.

Start Date01 Oct 2024

Sponsor / Collaborator

Centre Antoine-Lacassagne

100 Clinical Results associated with Centre Antoine-Lacassagne

0 Patents (Medical) associated with Centre Antoine-Lacassagne

1,946

Literatures (Medical) associated with Centre Antoine-Lacassagne

01 Jul 2024·Cancer

PEC‐PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent

Article

Author: Valentin, Thibaud ; Schöffski, Patrick ; Duffaud, Florence ; Chamseddine, Ali N ; Chevreau, Christine ; Chaigneau, Loïc ; Soibinet-Oudot, Pauline ; Severac, François ; Bertucci, François ; Weingertner, Noëlle ; Gantzer, Justine ; Ryckewaert, Thomas ; Charon-Barra, Céline ; Bozec, Laurence ; Le Loarer, François ; Follana, Philippe ; Blay, Jean-Yves ; Rioux-Leclercq, Nathalie ; Malouf, Gabriel G ; Firmin, Nelly ; Hervieu, Alice ; Bourgmayer, Agathe ; Toulmonde, Maud ; Kurtz, Jean-Emmanuel ; Vinson, Charles ; Brahmi, Mehdi ; Bompas, Emmanuelle

AbstractBackgroundPerivascular epithelioid cell neoplasms (PEComas) encompass a heterogeneous family of mesenchymal tumors. Previously described clinicopathologic features aimed at distinguishing benign from malignant variants but lacked prognostic value.MethodsThis retrospective analysis examined clinicopathologic data from patients who had localized PEComa across French Sarcoma Network centers. The authors analyzed 12 clinicopathologic features in a Cox proportional hazard framework to derive a multivariate prognostic risk model for event‐free survival (EFS). They built the PEComa prognostic score (PEC‐PRO), in which scores ranged from 0 to 5, based on the coefficients of the multivariate model. Three groups were identified: low risk (score = 0), intermediate risk (score = 1), and high risk (score ≥ 2).ResultsAnalyzing 87 patients who had a median 46‐month follow‐up (interquartile range, 20–74 months), the median EFS was 96.5 months (95% confidence interval [CI], 47.1 months to not applicable), with 2‐year and 5‐year EFS rates of 64.7% and 58%, respectively. The median overall survival was unreached, with 2‐year and 5‐year overall survival rates of 82.3% and 69.3%, respectively. The simplified Folpe classification did not correlate with EFS. Multivariate analysis identified three factors affecting EFS: positive surgical margins (hazard ratio [HR], 5.17; 95% CI, 1.65–16.24; p = .008), necrosis (HR, 3.94; 95% CI, 1.16–13.43; p = .030), and male sex (HR, 3.13; 95% CI, 1.19–8.27; p = 0.023). Four variables were retained in the prognostic model. Patients with low‐risk PEC‐PRO scores had a 2‐year EFS rate of 93.7% (95% CI, 83.8%–100.0%), those with intermediate‐risk PEC‐PRO scores had a 2‐year EFS rate of 67.4% (95% CI, 53.9%–80.9%), and those with high‐risk PEC‐PRO scores had a 2‐year EFS rate of 2.3% (95% CI, 0.0%–18.3%).ConclusionsThe PEC‐PRO score reliably predicts the risk of postoperative recurrence in patients with localized PEComa. It has the potential to improve follow‐up strategies but requires validation in a prospective trial.

19 Jun 2024·Journal of Physics: Condensed Matter

Silica-based scintillators: basic properties of radioluminescence kinetics

Article

Author: Hérault, Joël ; Mady, Franck ; Hofverberg, Petter ; Vidal, Marie ; Benabdesselam, Mourad ; Grandvillain, Marjorie

AbstractRadioluminescent silica-based fiber dosimeters offer great advantages for designing miniaturized realtime sensors for high dose-rate dosimetry. Rise and fall kinetics of their response must be properly understood to better assess their performances in terms of measurement speed and repeatability. A standard model of radioluminescence (RL) has already been quantitatively validated for doped silica glasses, but beyond conclusive comparisons with specific experiments, a comprehensive understanding of the processes and parameters determining transient and equilibrium kinetics of RL is still lacking. We analyze in detail the kinetics inherent in the standard RL model. Several asymptotical regimes in the RL growth are demonstrated in the case of a pristine sample (succesive quadratic, linear and power-law time dependencies before the plateau is reached). We show how this situation is modified when a pre-irradiation partly fills traps beforehand. RL growth is then greatly accelerated because of the pre-formation of recombination centers (RCs) from dopant ions, but not due to pre-filling of trapping levels. In all cases, the RL intensity eventually tends to a constant level equal to the pair generation rate, long before all carrier densities themselves reach equilibrium. This occurs late under irradiation, when deep traps get to saturation. The fraction of dopants converted into RCs is then ‘frozen’ at a lower level the smaller the density of deep traps. Controlling RL kinetics through the engineering of material traps is not an option. Pre-irradiation appears to be the simplest way to obtain accelerated and repeatable kinetics.

01 Jun 2024·The Breast

French college of gynecologists and obstetricians (CNGOF) recommendations for clinical practice: Place of breast self-examination in screening strategies

Review

Author: Luporsi, Élisabeth ; Chabbert-Buffet, Nathalie ; Fritel, Xavier ; Alghamdi, Khalid ; Vaysse, Charlotte ; Franck, Sophie ; Taris, Nicolas ; Maugard, Christine M ; Kermarrec, Edith ; Boutet, Gérard ; Sabah, Jonathan ; Mathelin, Carole ; Favier, Amélia ; Brousse, Susie ; Boisserie-Lacroix, Martine ; Uzan, Catherine ; Lavoue, Vincent ; Seror, Jean-Yves ; Delpech, Yann ; Azuar, Anne-Sophie ; Molière, Sébastien ; Golfier, François

Breast cancer is the most common female cancer in the world. Numerous studies have shown that the risk of metastatic disease increases with tumor volume. In this context, it is useful to assess whether the regular practice of formal breast self-examination (BSE) as opposed to breast awareness has an impact on the number of cancers diagnosed, their stage, the treatments used and mortality.DESIGNThe Commission of Senology (CS) of the Collège National de Gynécologie et Obstétrique Français (CNGOF) respected and followed the Grading of Recommendations Assessment, Development and Evaluation method to assess the quality of the evidence on which the recommendations were based.METHODSThe CS studied 16 questions individualizing four groups of women (general population, women aged over 75, high-risk women, and women previously treated for breast cancer). For each situation, it was determined whether the practice of BSE versus abstention from this examination led to detection of more breast cancers and/or recurrences and/or reduced treatment and/or increased survival.RESULTSBSE should not be recommended for women in the general population, who otherwise benefit from clinical breast examination by practitioners from the age of 25, and from organized screening from 50 to 74 (strong recommendation). In the absence of data on the benefits of BSE in patients aged over 75, for those at high risk and those previously treated for breast cancer, the CS was unable to issue recommendations. Thus, if women in these categories wish to undergo BSE, information on the benefits and risks observed in the general population must be given, notably that BSE is associated with a higher number of referrals, biopsies, and a reduced quality of life.

100 Deals associated with Centre Antoine-Lacassagne

100 Translational Medicine associated with Centre Antoine-Lacassagne

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 08 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Centre Antoine-Lacassagne

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 08 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing